Research and Development

OTC BioTech specializes in a rare technology and there are relatively few individuals and U.S. companies in this field with in-depth expertise in the selection and use of aptamers;

Research is conducted in a fully-equipped scientific laboratory complex with over 3500 square feet of laboratory and office space for the biotechnology group at OpTech’s corporate headquarters in San Antonio, Texas. The space is composed of a secure five-room 875 sq. ft. biotechnology laboratory adjacent to 1,155 sq. ft. of office space, as well as a separate chemistry laboratory (approximately 900 sq. ft.) and an additional laboratory annex (600 sq. ft).

Latest News

Research Partners
OTC BioTech seeks to expand our research and teaming agreements as well as creating new strategic alliances with non-government research partners to enhance the OTC BioTech research performance capabilities.
OTC Biotech Validates Killing of Cancer Cells with Aptamers in Recently Accepted Publication
Stecker J.R., Savage A., Bruno J.G., Garcia D.M., Koke J.R. Dynamics and visualization of MCF7 adenocarcinoma cell death by aptamer-C1q-mediated membrane attack. Nucleic Acid Therapeutics. In Press, 2012.
OTC Biotech's Aptamers Used for Surface-Enhanced Raman Spectroscopy (SERS) Detection
The following paper: "Concentration, detection and discrimination of Bacillus anthracis spores in orange juice using aptamer based surface enhanced Raman spectroscopy" by He et al. was recently published in the February 2013 issue of the Analyst and successfully utilized one of OTC Biotech's Bacillus spore aptamers linked to silver nanoparticles called "dendrites" for SERS-based detection. Dr. Bruno is also a co-author with several researchers at Cornell University on an upcoming article entitled "New aptasensor based on polymer-gold nanoparticles composite microspheres for the detection of malathion using surface-enhanced Raman spectroscopy" to be published soon in Industrial Biotechnology. These peer-reviewed journal articles are part of a growing body of literature utilizing OTC Biotech's DNA aptamers in various assay formats. Check back for more examples of our aptamer usage in the literature or send us your data and papers that use OTC Biotech aptamers. We will be glad to post and publicize them.

Capabilities

OTC BioTech is highly competent in the aptamer development process and with Dr. Bruno as its CTO is a leading U.S. expert in this technology as evidenced by the number of aptamer sequences submitted for patenting (over 3,000) and > 40 scientific peer-reviewed articles published and 2 book chapters and a new book on Biomedical Applications of Aptamers

OTC BioTech has developed aptamers that will bind to many different targets, including bacteria, viruses, parasites, toxins, select biomarkers and small molecules. OTC BioTech has incorporated magnetic beads and fluorescent nanoparticles with aptamers to allow target-matrix magnetic separation and facilitate ultra-sensitive and rapid detection of small numbers of organisms or minute molecular levels of the target.

Aptamers have also been developed using fluorescent dyes within the aptamer molecular chain to produce fluorescence resonance energy transfer (FRET) in “one-step” bind and detect assay systems. Biologically active aptamer conjugates have been produced to kill bacterial cells and cancer cells.

Cooperative Research and Development Agreements (CRADA’s)

Legislated by the Federal Technology Transfer Act of 1986, a CRADA is a Cooperative Research and Development Agreement. It is a written agreement between a private company and a government agency to work together on a project. CRADA vehicles provide incentives that can help speed the commercialization of Federally-developed technology, making them excellent technology transfer tools.

OTC BioTech has developed CRADA’s with Walter Reed Army Institute of Research, and the United States Army Medical Research Institute for Infectious Diseases.

Strategic Alliances

OTC BioTech has partnered with several universities to conduct research including:

  • Texas State University, San Marcos, TX
  • University of Texas-Pan American, Edinburgh, TX
  • The University of Texas Health Science Center- San Antonio, San Antonio, TX
  • The University of Texas San Antonio, San Antonio, TX

OTC BioTech has agreements in place with research and production laboratories, engineering firms as well as assay manufacturing partners. National and international partners are sought to enhance research and commercialization capabilities.